Caribou Biosciences' high P/S ratio, despite expected revenu...
Caribou Biosciences' high P/S ratio, despite expected revenue slump and industry's predicted 250% growth, may worry investors. A potential disappointment awaits if the P/S aligns with the negative growth outlook.
There's Reason For Concern Over Caribou Biosciences, Inc.'s (NASDAQ:CRBU) Massive 25% Price Jump
免责声明:以上信息不代表Moomoo Technologies Inc.("MTI")的任何立场,不构成与MTI及其关联公司的任何投资建议。
更多信息
评论
登录发表评论